Drug intelligence / Profile preview

lidocaine + sufentanil

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous, Topical, Epidural, Intrathecal

Overview

Lidocaine + sufentanil is a combination of two drugs used in anesthesia and pain management. Lidocaine is a local anesthetic that works by blocking sodium channels to prevent pain signals from being transmitted by nerves. Sufentanil is a potent opioid analgesic and a specific μ-opioid receptor agonist with fast onset of action, strong analgesic effect, and good hemodynamic stability. The combination is used in various medical procedures including upper gastrointestinal endoscopy and potentially for other types of anesthesia or analgesia.

Other names: sufentanil and lidocainesufentanil plus lidocaine

Targets

MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on lidocaine + sufentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + sufentanil.

Explore the full profile